Wang Yuanyuan, Zeng Yanqiong, Zhu Linyu, Wan Jiajia, Lei Ningjing, Yao Xiaohan, Duan Xixi, Zhang Yana, Cheng Yanru, Tao Ning, Qin Zhihai
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
School of Basic Medical Sciences of Southwest Medical University, Luzhou, China.
Front Oncol. 2021 Feb 12;10:547683. doi: 10.3389/fonc.2020.547683. eCollection 2020.
Polysaccharides from () have been successfully used as adjuvant chemotherapy drug to treat lymphatic metastasis in some malignancies, such as colorectal cancer (CRC), lung cancer and gastric cancer. The CRC could metastasize lymphatic vessels. Lymphatic metastasis is commonly thought to be the cause of poor prognosis of CRC. The mechanism of polysaccharides from inhibiting lymphatic metastasis of CRC is still unclear. In this study, we explored how MPSSS, a novel polysaccharide component of , influences lymphangiogenesis and lymph node metastasis. The results show that MPSSS can reduce lymphangiogenesis and lymphatic metastasis of CRC in mouse model. And combined with study, a likely mechanism is that MPSSS reduce the secretion of VEGF-C by cancer associated fibroblasts (CAFs). This effect can be suppressed by a TLR4 inhibitor, which suggests that MPSSS plays a role in CAFs through the TLR4/JNK signaling pathway. In conclusion, MPSSS may reduce lymphangiogenesis by decreasing the VEGF-C secretion of CAFs, which may provide a new strategy for the comprehensive treatment of CRC.
[具体来源]中的多糖已成功用作辅助化疗药物,用于治疗某些恶性肿瘤(如结直肠癌(CRC)、肺癌和胃癌)的淋巴转移。结直肠癌可通过淋巴管转移。淋巴转移通常被认为是结直肠癌预后不良的原因。[具体来源]中的多糖抑制结直肠癌淋巴转移的机制仍不清楚。在本研究中,我们探讨了[具体来源]的一种新型多糖成分MPSSS如何影响淋巴管生成和淋巴结转移。结果表明,MPSSS可减少小鼠模型中结直肠癌的淋巴管生成和淋巴转移。结合[相关]研究,一种可能的机制是MPSSS减少癌相关成纤维细胞(CAFs)分泌VEGF-C。TLR4抑制剂可抑制这种作用,这表明MPSSS通过TLR4/JNK信号通路在CAFs中发挥作用。总之,MPSSS可能通过减少CAFs分泌VEGF-C来减少淋巴管生成,这可能为结直肠癌的综合治疗提供一种新策略。